JP2002531552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531552A5 JP2002531552A5 JP2000586696A JP2000586696A JP2002531552A5 JP 2002531552 A5 JP2002531552 A5 JP 2002531552A5 JP 2000586696 A JP2000586696 A JP 2000586696A JP 2000586696 A JP2000586696 A JP 2000586696A JP 2002531552 A5 JP2002531552 A5 JP 2002531552A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cycloalkyl
- pharmaceutically acceptable
- alkyl
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010048994 Bladder spasm Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000003274 myotonic effect Effects 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 201000009881 secretory diarrhea Diseases 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- PHJOFWDUFPTPDH-UHFFFAOYSA-N 4,5-dichloro-1,3-diethylbenzimidazol-2-one Chemical compound C1=C(Cl)C(Cl)=C2N(CC)C(=O)N(CC)C2=C1 PHJOFWDUFPTPDH-UHFFFAOYSA-N 0.000 description 1
- ZHJISUUEKCREGX-UHFFFAOYSA-N 6,7-dichloro-3-ethyl-1h-benzimidazol-2-one Chemical compound C1=C(Cl)C(Cl)=C2NC(=O)N(CC)C2=C1 ZHJISUUEKCREGX-UHFFFAOYSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801610 | 1998-12-04 | ||
| DK199801610 | 1998-12-04 | ||
| PCT/DK1999/000681 WO2000034248A1 (en) | 1998-12-04 | 1999-12-03 | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002531552A JP2002531552A (ja) | 2002-09-24 |
| JP2002531552A5 true JP2002531552A5 (enExample) | 2007-02-01 |
Family
ID=8106528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586696A Pending JP2002531552A (ja) | 1998-12-04 | 1999-12-03 | イオンチャネル調節剤としての新規ベンズイミダゾロン−、ベンズオキサゾロン−又はベンゾチアゾロン−誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6624186B2 (enExample) |
| EP (1) | EP1144387A1 (enExample) |
| JP (1) | JP2002531552A (enExample) |
| CN (1) | CN1177831C (enExample) |
| AU (1) | AU760250B2 (enExample) |
| CA (1) | CA2349616A1 (enExample) |
| NZ (1) | NZ511334A (enExample) |
| WO (1) | WO2000034248A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021487D0 (en) * | 2000-09-01 | 2000-10-18 | Pfizer Ltd | Pharmaceutical |
| EP1345618B1 (de) * | 2000-12-28 | 2005-03-23 | Switch Biotech Aktiengesellschaft | Chlorzoxazon zur behandlung von psoriasis |
| CA2438805A1 (en) * | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators of kcnq potassium channels |
| US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
| US7022480B1 (en) | 2001-10-11 | 2006-04-04 | The Regents Of The University Of California | Exons of the hSKCa3/KCNN3 gene |
| DE10231105A1 (de) | 2002-07-10 | 2004-01-22 | Clariant Gmbh | Neue Diketopyrrolopyrrolpigmente |
| AU2005201685B2 (en) * | 2002-10-21 | 2008-10-09 | Ramot At Tel Aviv University Ltd. | Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators |
| AU2003272068A1 (en) * | 2002-10-21 | 2004-05-04 | Ramot At Tel Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| DE10250870A1 (de) * | 2002-10-31 | 2004-05-13 | Switch Biotech Ag | Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung |
| WO2004064835A1 (en) * | 2003-01-17 | 2004-08-05 | Neurosearch A/S | Use of ion channel modulating agents for treating pain |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| CN101868443A (zh) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-苯基邻氨基苯甲酸衍生物及其用途 |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| KR20140095067A (ko) | 2011-10-28 | 2014-07-31 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서의 선택적 활성을 갖는 벤족사졸리논 화합물 |
| SG11201500585XA (en) * | 2012-10-29 | 2015-04-29 | Hoffmann La Roche | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2015004533A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| CN105294591B (zh) * | 2015-11-17 | 2017-05-10 | 河南大学 | 一种高立体和高对映选择性噁唑啉二酮类化合物、制备方法及其应用 |
| KR101751486B1 (ko) | 2016-03-02 | 2017-06-28 | 광주과학기술원 | BKCa 채널 활성화용 조성물 |
| JP7493454B2 (ja) | 2018-04-13 | 2024-05-31 | キャンサー・リサーチ・テクノロジー・リミテッド | Ｂｃｌ６阻害剤 |
| CN109701024B (zh) * | 2019-03-04 | 2020-12-11 | 复旦大学 | Bk通道开放剂的新用途 |
| NZ789439A (en) * | 2019-12-10 | 2025-07-25 | Shanghai Zhimeng Biopharma Inc | Compound having neuroprotective effect, preparation method therefor and use thereof |
| EP4466253A4 (en) * | 2022-01-17 | 2025-07-02 | Univ Ramot | SK4 POTASSIUM CHANNEL MODULATORS AND THEIR USES |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2927116A (en) * | 1960-03-01 | Chlorobenzimidazolone compounds | ||
| GB1363735A (en) * | 1970-10-23 | 1974-08-14 | Hoechst Ag | Process for the manufacture of benzimidazolones |
| CA1058191A (en) * | 1974-08-31 | 1979-07-10 | Karl Kuffner | Color photographic material containing new 2-equivalent yellow couplers |
| IT1106962B (it) * | 1977-01-17 | 1985-11-18 | Sumitomo Chemical Co | Composit derivati del benzossa tiazolone utilizzabili particolarmente come fungicidi |
| US4420486A (en) * | 1981-01-22 | 1983-12-13 | Hokko Chemical Industry Co., Ltd. | Benzoxazolone derivatives, processes for preparation thereof and compositions containing them |
| DE3839743A1 (de) | 1988-11-25 | 1990-05-31 | Hoechst Ag | Verfahren zur herstellung von benzimidazolonen |
| EP0401582B1 (de) * | 1989-06-01 | 1994-07-20 | BASF Aktiengesellschaft | Fünfring-heterocyclisch anellierte Chinolinderivate |
| ATE159251T1 (de) * | 1990-08-29 | 1997-11-15 | Upjohn Co | Tropolonderivate und pharmazeutische zubereitungen davon zur vorbeugung und behandlung von ischämischen krankheiten |
| NZ239540A (en) * | 1990-09-24 | 1993-11-25 | Neurosearch As | 1-phenyl benzimidazole derivatives and medicaments |
| US5296493A (en) * | 1991-05-23 | 1994-03-22 | Neurosearch A/S | 1-substituted-2-(N-phenyl-N-(phenylmethyl)methanamine)-4,5-dihydro-imidazoles and related compounds and their use in treating calcium overload in brain cells |
| US5314903A (en) * | 1991-12-03 | 1994-05-24 | Neurosearch A/S | Benzimidazole compounds useful as calcium channel blockers |
| DK40192D0 (da) * | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| DE19539114C1 (de) | 1995-10-20 | 1997-04-17 | Hoechst Ag | Verfahren zur Aufarbeitung von Benzimidazolone enthaltenden Reaktionsgemischen |
| AR019678A1 (es) | 1998-06-18 | 2002-03-13 | Novartis Ag | Compuestos organicos |
| GB0008939D0 (en) | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
-
1999
- 1999-12-03 CN CNB99813936XA patent/CN1177831C/zh not_active Expired - Fee Related
- 1999-12-03 AU AU15498/00A patent/AU760250B2/en not_active Ceased
- 1999-12-03 JP JP2000586696A patent/JP2002531552A/ja active Pending
- 1999-12-03 EP EP99957967A patent/EP1144387A1/en not_active Withdrawn
- 1999-12-03 NZ NZ511334A patent/NZ511334A/xx not_active IP Right Cessation
- 1999-12-03 WO PCT/DK1999/000681 patent/WO2000034248A1/en not_active Ceased
- 1999-12-03 CA CA002349616A patent/CA2349616A1/en not_active Abandoned
-
2001
- 2001-05-15 US US09/854,357 patent/US6624186B2/en not_active Expired - Fee Related
-
2003
- 2003-07-01 US US10/609,607 patent/US20040029937A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531552A5 (enExample) | ||
| US20240166605A1 (en) | Process for the preparation of a pde4 inhibitor | |
| WO2006046499A1 (ja) | インドリン化合物およびその製造方法 | |
| DE69922997D1 (de) | Verwendung von isatinderivaten als ionenkanalaktivierende mittel | |
| TWI294878B (en) | Dioxan-2-ylalkylcarbamate derivatives, their preparation and their use in therapeutics | |
| JP2002519412A5 (enExample) | ||
| TW200825039A (en) | 4-substituted phenoxyphenylacetic acid derivatives | |
| JP2008520745A5 (enExample) | ||
| US9765026B2 (en) | Forms of apremilast and the process of making the same | |
| JP2005508349A5 (enExample) | ||
| JP2011500696A5 (enExample) | ||
| US8288401B2 (en) | Polymorphic forms | |
| AU4768999A (en) | Potassium channel blocking agents | |
| JP2020535168A5 (enExample) | ||
| JP2002531539A5 (enExample) | ||
| WO2006022252A1 (ja) | アミノチアゾール誘導体の製造法及び製造中間体 | |
| JP2008543915A5 (enExample) | ||
| JP2007514001A (ja) | ジプラシドン塩基の多形形態ｂ２ | |
| JPWO2010055911A1 (ja) | ビフェニルアセトアミド誘導体 | |
| TW201002710A (en) | Novel (bridged piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors | |
| JP2009542602A5 (enExample) | ||
| JP2007513863A (ja) | 新規化合物 | |
| CN102271505A (zh) | (2-氨基)-四氢咔唑-丙酸的合成 | |
| GB2419592A (en) | Process for the preparation of irbesartan hydrochloride | |
| CN103068392A (zh) | 苯甲酸阿格列汀的多晶形物 |